Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

Point-of-Care Diagnostics for Ebola

publication date: Aug 24, 2015
 | 
author/source: Integrated DNA Technologies

IDT’s Ebola PrimeTime® qPCR Assay Validated

scientists Kristin Beltz and Dr Scott RoseIn a recent DECODED research profile, Integrated DNA Technologies (IDT), details how IDT scientists Kristin Beltz and Dr Scott Rose are collaborating with Dr Brian Taylor’s research team at Battelle (Aberdeen, MD, USA) to design and validate a RT-qPCR assay that can detect the Ebola virus in the field. The IDT PrimeTime® Ebola qPCR Assay detects Zaire ebolavirus, the species involved in the 2013–2015 West African Ebola outbreak. Initial sensitivity and specificity results were presented at the 2015 Chemical and Biological Defense Science and Technology Conference (St. Louis, MO, USA). The researchers noted that the assay has a PCR efficiency of 98.9% and that use of ZEN™ Double-Quenched Probes (IDT) lowers assay background and increases signal compared to traditional single-quenched probes in qPCR assays.

It can be difficult to distinguish Ebola from other infectious diseases, and current diagnostic tests are time-consuming and complex. They also create challenges related to sample storage and transportation, laboratory biosafety, and staff expertise in performing the assays. Having access to simple, rapid, and accurate viral testing in remote villages would be extremely useful for quelling this and future epidemics. With this goal in mind, Dr Paul Pickering (Ubiquitome Limited, Auckland, New Zealand) is spearheading the project to develop the assay for use with the Ubiquitome Freedom4 device. This portable PCR machine processes 4 reactions (sample plus negative, positive, and extraction controls) in approximately 1 hour, and is easily controlled via an iPhone or laptop. The Freedom4 device eliminates the need for sample preservation and transportation to a laboratory-based testing facility, and can simply be brought to remote locations for use during time-sensitive, public health situations.

The Freedom4 and the PrimeTime Ebola qPCR Assay are now being submitted to the US FDA for Emergency Use Authorization. Find out more about the rapid point-of-care diagnostic test for Ebola by reading the full article online.


more about integrated DNA technologies


more news from integrated DNA technologies


 


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners